The International Aspirin Foundation Scientific Conference 2019 is attracting worldwide speakers.
Sign up to be part of the aspirin community and be the first to receive latest information.
Have something to say about aspirin?
Our biennial conference is a great opportunity to hear from leading biomedical researchers across a range of specialties. By coming together discuss the latest international data, we can enhance understanding, build stronger networks and inspire new ideas.
The International Aspirin Foundation Scientific Conference 2019 is attracting worldwide speakers.
Professor Peter Rothwell qualified in medicine from the University of Edinburgh in 1987 and after completing his early postgraduate clinical training he moved to Oxford as Clinical Lecturer in Neurology in 1996. Professor Peter Rothwell was awarded an MRC Senior Clinical Fellowship in 1999 and set up the Stroke Prevention Research Unit in 2000, which now employs over 40 research staff. He was awarded a Professorship in 2004 and was elected a fellow of the Academy of Medical Sciences in 2008, a National Institute of Health Research Senior Investigator in 2009 and a Wellcome Trust Senior Investigator in 2011. He has published over 500 scientific papers and several books. His research interests include primary and secondary prevention of stroke, the effects of blood pressure on the brain, and the risks and benefits of aspirin.
Peter is clinically active, working as a Consultant Neurologist for the Oxford University Hospitals Trust, and is Founding Director of a new purpose-built Centre for Prevention of Stroke and Dementia on the John Radcliffe Hospital site.
Angel Lanas is Professor of Medicine of the University of Zaragoza, Vice-Dean for Research Affairs at the Medical School of Medicine University of Zaragoza, Chairman of the Digestive Diseases Service at the University Hospital “Lozano Blesa” of Zaragoza. Spain and Scientific Director of the Aragón Health Research Institute.
Dr. Lanas was visiting professor to the Department of Gastroenterology at the University of Alabama in Birmingham, Alabama, USA since November 1989 to Dicember1991, where he worked with Professor Basil Hirschowitz.
He is or has been member of the Advisory Board of several high-impact factor Journals of the specialty, International Associate Editor of The American Journal of Gastroenterology and Editor of Frontiers in Medicine-Gastroenterology. He has also been invited as Visiting Professor to different American, Asian and European Universities. Over the years, he has held leadership positions and received numerous awards for his contributions
Among other associations he is member and International Fellow of the American Gastroenterological Association, member of the General Assembly of the United European Gastroenterology Federation and the Spanish Association of Gastroenterology (AEG). He was president of the AEG for 4 years and President of the AEG Foundation for another 4 years.
Dr. Lanas is actively involved in both clinical and basic investigation relating to acid peptic disorders, particularly NSAIDs, aspirin and gastrointestinal toxicity, as well as mechanisms of chemoprevention of colon cancer and Barrett’s esophagus. Professor Lanas has published numerous articles pertaining to gastrointestinal damage, NSAIDs and inflammation in the most prestigious Medical Journals including the New England Journal of Medicine, The Lancet, Gastroenterology, Gut, The American Journal of Gastroenterology and American Journal of Medicine among others.
Professor of Pharmacology, Department of Neuroscience, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences, “G. d’Annunzio” University, Chieti, Italy.
Paola Patrignani was graduated at the Faculty of Biological Sciences, “La Sapienza” University of Rome (Italy). Then, she followed a doctoral training in Pharmacology, at Catholic University of Rome, Italy. She worked for 2 years as Postdoctoral Research Fellow at Le Centre Hospitalier of Laval University (Quebec, Canada) and at the Department of Pharmacology of Merck Frosst (Kirkland, Quebec, Canada).
She continued her academic career at “G. d’ Annunzio” University, School of Medicine, Chieti, Italy, where she is currently Professor of Pharmacology and Head of the Laboratory of Systems Pharmacology and Translational Therapeutics at the Center of Excellence on Aging and Translational Medicine (CeSI-MeT).
In 2009 she was Guest professor of Pharmacology at Goethe-Universität Frankfurt am Main (Germany). She is a member of the Italian Society of Pharmacology and she received the Upjohn Award (1981), the “Henry Christian” Award (1991) and was the winner of the 2018 International Aspirin Foundation Senior Science Award. In 2013, she received a special prize awarded by the Committee for the Promotion of Female Entrepreneurship of Abruzzo Region (Italy).
She is one of the Top Italian Women Scientists (TWIS) which includes the scientists with high impact publications. Her scientific activity is documented by 170 peer-reviewed publications in international journals ranked in the Journal Citation Reports, and 21 chapters in national-international books. Her cumulative citation index (H-index) is 56, 11831 citations.
Short statements of expertise:
• Her research focuses on the study of the role of eicosanoids in inflammation, cancer and cardiovascular disease.
• She has contributed to the development of biomarkers predictive of the impact of NSAIDs on COX-1 and COX-2 activities in vitro, ex vivo and in vivo which have been essential to read-out the clinical consequences of selective and nonselective inhibition of COX-isozymes in humans.
• Her recent studies have allowed to clarify the determinants of NSAID toxicity for the gastrointestinal and cardiovascular systems which will be important for the development of personalized treatments in humans.
• She is performing an intense research activity with the aim of identifying the mechanisms of the anti- tumorigenic effects of antiplatelet agents, with particular interest in clarifying the mechanism of action of aspirin. To realize these aims her research group is integrating basic and clinical research in different biological systems using the “Omics” approach.
Professor Marco Cattaneo is Professor of Internal Medicine at Università degli Studi di Milano. He has been Post-Doctoral Fellow at McMaster University, Hamilton (Ontario), Guest or Visiting Scientist at McMaster University, Temple University, Philadelphia (PA), The Scripps Research Institute, La Jolla (CA). In 2001 he was awarded the International Society on Thrombosis and Haemostasis (ISTH) 10th Biennial Award for Contributions to Haemostasis and Thrombosis. Editor/Associate Editor/member of Editorial Board/Advisory Board for high-tier journals, including Jornal of Thrombosis and Haemostasis, Thrombosis Research, Haematologica, Platelets, Thrombosis and Haemostasis, Arteriosclerosis, Thrombosis and Vascular Biology. Professor Marco Cattaneo is also Chair of the Working Party on Platelet Aggregation, Chair of the Scientific Subcommittee on Platelet Physiology, Scientific and Standardization Committee (ISTH). Member of the ISTH Council 2010-2016. President-Elect, President and Past-President of SISET, the Italian Society on thrombosis and hemostasis, 2002-2008. Main research interests: pathophysiology of primary haemostasis, pharmacology of antiplatelet agents, risk factors for thromboembolism.
Medicina 2, ASST Santi Paolo e Carlo, Milan, Italy – Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy
2016 Extraordinary Professorship for invasive cardiology Bern University Hospital, Bern, Switzerland
2013 Associated Professorship Erasmus Medical Center, Rotterdam, The Netherlands
2006 PhD degree in Interventional Cardiology Erasmus Medical Center, Rotterdam, The Netherlands
Promoters Professors P.W. Serruys and P. de Feyter
2003 Degree in Cardiological Sciences University of Ferrara, Ferrara, Italy
Magna cum laude
1997 Doctor in Medicine and Surgery (equivalent to M.D.) University of Bologna, Italy, Magna cum laude
1991 – 1997 Medical studies, Faculty of Medicine, University of Bologna, Bologna, Italy
1991 High School degree in foreign languages (60/60)
FORMER POSITIONS AND CURRENT POSITION
Extraordinary Professor for invasive cardiology Bern University Hospital, Bern, Switzerland
Head of clinical research, Department of Cardiology, Inselspital, Bern University Hospital, Switzerland
Associate Professor of Cardiology at Erasmus Medical Center and Senior Interventional Cardiologist, Thoraxcenter, Rotterdam, The Netherlands
Director of the Catheterization Laboratory at the University Hospital of Ferrara, Ferrara, Italy
Senior attending cardiologist at the University Hospital of Ferrara working full time in the catheterization laboratory
Centre Hospitalier Universitaire de Caen, Avenue Côte de Nacre 14033 Caen, Normandy, France, Cedex (under the assistance of Prof M. Hamon)
Training in complex PCI procedures through radial access at the Centre Hospitalier Universitaire de Caen, Avenue Côte de Nacre Caen, Normandy, France, Cedex (under the assistance of Prof M. Hamon)
Research (PhD training) and clinical fellowship in Interventional Cardiology, Erasmus University, Thoraxcenter, Rotterdam, The Netherlands
Post-graduate Resident-fellow at Haemodynamic Unit, S. Anna Hospital, University of Ferrara, Ferrara, Italy
Post-graduate fellow at Haemodynamic Unit, Spedali Civili, University of Brescia, Brescia, Italy
Post-graduate fellow at Coronary Care Unit, S. Anna Hospital, University of Ferrara, Ferrara, Italy
Post-graduate fellow at Emergency Medicine Unit, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Residency in Internal and Emergency Medicine Sciences, winning a national grant University of Bologna, Bologna, Italy, (Prof Bolondi, Mentor)
Clerkship in Cardiology at Hospital de Santa Maria, Lisbon, Portugal
Student-fellow at 1 Internal Medicine Unit Departement, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
CURRENT APPROVED RESEARCH PROJECTS
SUPERVISION OF YOUNG RESEARCHERS
EAPCI Fellowship Dr. Giuseppe Gargiulo
PhD-Thesis Patrizia Malagutti, Elisa Merli, Olga Soukhomovskaia, Elisa Cangiano, Gianluca Campo, Carlo Penzo.
Giuseppe Gargiulo, Sara Ariotti, Francesco Costa, Marianna Adamo, Fortunato Iacovelli, Marco Angelillis
External Reviewer Dr. Emanuele Meliga (2010), Dr.Lorenz Räber (2015), Dr.Michele Magro (2015), Dr. forPhD Thesis Christian Puelacher (2017)
2014 – 2015 Responsible Person of the COEUR course on anti-thrombotics devoted to PhD students of the Erasmus Medical Center institution
2013 Contract professor of invasive cardiology for nurses at the University of Ferrara
2013 Contract professor of invasive cardiology for radiology technicians at the University of Ferrara
2013 Contract professor of invasive cardiology for residents in the specialization course of Cardiology at the University Hospital of Ferrara Italy
MEMBERSHIPS IN PANELS, BOARDS AND INDIVIDUAL SCIENTIFIC EXPERT-ACTIVITIES
Editorial board member: Journal of the American College of Cardiology – Cardiovascular Interventions; EuroIntervention; Future Cardiology; Asia Pacific Intervention
Reviewer for most relevant peer-reviewed Journals in Cardiology (European Heart Journal, Journal of American College of Cardiology (JACC), Circulation, JACC Cardiovascular Interventions, Eurointervention, etc.) and Internal Medicine (New England Journal of Medicine, Lancet, Journal of the American Medical Association (JAMA), etc.)
Reviewer “ESC Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndrome” 2012
Reviewer Coordinator “ESC Guidelines for the Diagnosis and Treatment of Stable Coronary Artery Disease” 2012-2014
Task Force Member “ESC Guidelines for the Management of ST-Segment Elevation Myocardial Infarction” 2011-2012
Task Force Member “ESC Guidelines on Myocardial Revascularization. Task Force on Myocardial Revascularization of the
European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)” 2012-2014
Task Force Member (Section Coordinator) “ESC Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndromes” 2013-2015
Chair-Task Force 2015-2017 “ESC Guidelines DAPT Focused Update on Myocardial Revascularization. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio -Thoracic Surgery (EACTS)”
Elected Co-chair person 2019-2021 of the 2021 ESC guidelines ESC for the Diagnosis and Treatment of ST Segment Elevation Myocardial Infarction
ACTIVE MEMBERSHIP OF SCIENTIFIC SOCIETIES
2013 – 2014 Editor of the ESC Congress News
Since 2013 Committee Member, Congress Program Committee
Since 2015 Chair, Congress Program Committee
Since 2011 Chair, Research Committee from the European Association of Percutaneous Coronary intervention (EAPCI)
Since 2011 Committee member Program, TCT-course on cardiovascular interventions, New York, USA
Since 2010 Committee Program Member, PCR-course on cardiovascular interventions, EuroPCR, Paris, France
Since 2007 Fellow of the European Society of Cardiology (ESC
Since 2006 Committee Member, European Societyof Cardiology (ESC)
ORGANISATION OF CONFERENCES, MEMBER OF SCIENTIFIC PROGRAMME COMMITTEE
2015-2016 ESC CPC program coordinator
2012-2013 ESC CPC – Congress Programme Committee
From 2010 TCT
From 2009 ACC/SCAI
From 2008 EuroPCR
PRIZES, AWARDS, FELLWOSHIPS
Clinical and Research Fellowship in Interventional Cardiology, Erasmus University, Thoraxcenter, Rotterdam, The Netherlands (Mentor, Prof P.W. Serruys) 2004 – 2005
Winner of the “Best Scientific contribution Award”, October 2002, Verona, Italy, on behalf of GISE (Gruppo Italiano Studi di Emodinamica)
Winner of the “Scholarship from Italian Society of Cardiology”, Rome 2003, Italy, SIC (Italian Society of Cardiology)
Finalist TCT Young Investigator Award, October 2005, Washington
Major Scientific achievements
Valgimigli’s research influenced both European and American guidelines for clinical practice in multiple
aspects, impacting on coronary stent selection as well indications and regimens of various anti-thrombotic drugs and choice of access site during coronary intervention. Valgimigli has been first member or reviewer of multiple ESC guidelines task forces, and he then acted the chair of the European focused update guidelines on dual antiplatelet therapy. As clinical trialist, Valgimigli has acted as Principal Investigators of multiple investigator initiated global prospective randomized studies in the field of interventional cardiology, including the Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS; NCT01385319) and the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX; NCT01433627) program which encompassed three different randomization schemes in a quasi factorial study design. For both projects, Valgimigli has conceived and designed the studies, identified possible grant givers and successfully secured the funding for their conduct, overseen sponsor’s and clinical research organizations’ activities and finally published the results in multiple peer review journals.
In the filed of personalised medicine, Valgimigli has recently published in the Lancet journal the development and external validation of the PRECISE DAPT score, which has been shown to discriminate between net clinical benefits versus net clinical harm in regards to a prolonged course of DAPT therapy in largely unselected patients undergoing percutaneous coronary intervention.
Valgimigli’s research focus has also embraced the field of inflammation and its interaction with reactive oxygen species in patients with prior myocardial infarction progressing or not progressing towards over heart failure as well the characterization of bone marrow stem cells mobilisation in relation to an acute ischemic or non ischemic myocardial injury or in patients with over heart failure in relation to the severity of the disease. Finally, Valgimigli pioneered the filed of bone marrow stem cells mobilisation with the use of granulocyte colony stimulating factor in order to promote myocardial regeneration and repair in patients having suffered from myocardial infarction.
Valgimigli has received in 2017 the 2017 highly cited researcher award from the Institute for Scientific
Information (ISI) in recognition of ranking the top 1% of researchers for most cited documents, in Clinical
Prof. Lina Badimon is the Director of the Cardiovascular Science Program (ICCC) at the IR-Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research. She is the Chair of the Advocacy Committee and Board Member 2018-2020 of the European Society of Cardiology.
Her research activities focus on cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease.
She has published over 560 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (Citations: 41.241; h‐index 76). She has written more of 250 reviews and book chapters.
She is Member of Editorial Boards of various international scientific journals. Previous appointments include: Fellow in Cardiovascular Diseases at The Mayo Clinic, Rochester, MN, USA (1981‐1983); Director of the Cardiology Basic Research Laboratory of the Division of Cardiology at the Mount Sinai Medical Center, New York, NY (1983‐1991); Assistant Professor of Medicine (1983‐1987) and Associate Professor of Medicine (1988‐1991) at the Mount Sinai School of Medicine, NY; Lecturer in Medicine at Harvard Medical School, Boston (1991‐1994); Consultant at the Cardiac Unit, at the Massachusetts General Hospital, Boston (1991‐1994)
Positions of Trust: Vice-President for Scientific Affairs of European Society of Cardiology (2016-2018), Vice‐President of the Spanish Society of Cardiology (2013‐2015); Chairman of the Council on Basic Cardiovascular Science (2014‐2016) and Chairman of the Working Group on Microcirculation (2012‐2014) of the ESC; Past‐President of the European Society for Clinical Investigation (2000‐2002) and Past‐President of the Spanish Society of Atherosclerosis (1996‐2000); Member of the National Academy of Medicine and of the National Academy of Pharmacy of Catalonia and Spain.
Honorary Appointments: Fellow of the Cardiovascular Science Council and Fellow of the Atherosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association; Fellow of the European Society of Cardiology; Distinguished Fellow of the International Atherosclerosis Society; Honorary Member of Spanish Society of Hypertension, of the Romanian Society of Hypertension, of Hungarian Society of Cardiology, of “Sociedad Peruana de Cardiologia” and Spanish Society of Arteriosclerosis. She has received the “Narcís Monturiol” (1993) and “Creu de Sant Jordi” (2004) Medals from Generalitat de Catalunya; the “Rey Jaime I” Award – Medical Research (2014) from Generalitat Valenciana and named Doctor Honoris Causa by the Carol Davila University of Medicine and Pharmacy, Romania (2015).
Professor Ruth Langley is a Medical Oncologist specializing in the design and management of oncology clinical trials based at the MRC Clinical Trials Unit at University College London where she leads the Cancer Group. Professor Ruth Langley has worked in a number of tumour areas including colorectal, lung and gastro-oesophageal cancer coordinating a series of trials and associated translational studies. She has a particular interest in re-purposing established medicines as cancer therapeutics, as well as cancer prevention, and as Chair of the UK Therapeutic Cancer Prevention Network. She has led the investigation of the use of transdermal oestrogen as a treatment for prostate cancer (PATCH studies). A major focus of her recent work has been the development of an international trial to assess the effect of aspirin as an adjuvant agent in several common solid tumours (the Add-Aspirin Trial) which is recruiting patients from the UK, Ireland and from several sites across India. The Add-Aspirin trial is part of a Cancer Research UK funded initiative the AsCaP collaboration to investigate the mechanisms underlying the anti-cancer effects of aspirin. She is a faculty member of the Indian CReDO (Collaboration for Research methods Development in Oncology) programme.
Professor Bianca Rocca, MD, PhD is Associate Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy). Professor Bianca Rocca trained as Postdoctoral Fellow at the Center for Experimental Therapeutics, University Pennsylvania of Philadelphia (USA) with Prof. Garret A. FitzGerald. She is immediate Past Chairperson of the European Society of Cardiology (ESC) Working Group on Thrombosis (2018-2020) and ex officio Member of the board of the ESC Working Group on Aorta and Peripheral Vascular Disorders. She is member of the Board of Clinical Pharmacology of the Italian Society of Pharmacology and of the Board of the Italian Group of Atherosclerosis, Thrombosis and Vascular Biology.
She has been part of several Task Forces of guidelines and position papers within the ESC. She has co-authored over 110 articles in peer-reviewed journals with over 6500 citations, including Nature Medicine, Science, Blood, Circulation, Journal of Clinical Investigation, PNAS (USA), Annals of Internal Medicine, ATVB, Nature Clinical Practice in Cardiovascular Medicine, JACC, European Heart Journal, Diabetes. Her H-index is 41. Main scientific topics of interest are antithrombotic drugs, eicosanoids, primary haemostasis, platelets, non-steroidal anti-inflammatory drugs, cardiovascular diseases.
Andrew T. Chan, MD, MPH, Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston. As a clinical gastroenterologist, Dr. Chan specializes in familial gastrointestinal cancer syndromes and cancer prevention. Dr. Chan is a leading investigator in the epidemiology of colorectal cancer and other digestive diseases, with a focus on chemoprevention with aspirin and the gut microbiome.
An elected fellow of the American Society of Clinical Investigation, his work is supported by the National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, Cancer Research UK, the American Gastroenterological Association (AGA), the Damon Runyon Cancer Research Foundation, and the Crohn’s and Colitis Foundation of America. He has published over 380 papers in the field of colorectal cancer and other chronic digestive diseases in leading journals, including the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Science Translational Medicine, Gastroenterology and Gut. In 2016, he was recognized with a Top Ten Clinical Research Achievement award by the Clinical Research Forum. Dr Chan is a section editor for Gastroenterology, serves on the editorial board of Cancer Prevention Research and Cancer Epidemiology Biomarkers and Prevention, and is Chair of the Gastrointestinal Oncology Section of the AGA.
Prof. Francesco Cosentino obtained his MD degree in 1987 and specialty training in Internal Medicine and Cardiovascular Disease at the University of Rome. In 1991 moved to Mayo Clinic & Foundation, Rochester, MN, USA for a Cardiovascular Fellowship. During his stay at Mayo he fulfilled all the requirements for a PhD in Biomedical Sciences – Cardiovascular Pharmacology. In 1995, he joined the Cardiovascular Division at the University Hospital of Bern. Two years later, Francesco Cosentino moved to the Division of Cardiology of Zurich University Hospital as “lecturer” and then “titular professor” of Cardiology. In 2006, he was appointed associate professor of Cardiology at the University of Rome “Sapienza”.
Since 2013 he is professor and chair of Cardiovascular Medicine, Karolinska University Hospital, Solna and Karolinska Institute in Stockholm.
Prof. Cosentino is the recipient of grants and prizes from national and international institutions, research councils and private foundations. He is the leading author of more than 150 original articles published in top-ranking, peer-reviewed journals.
Prof. Cosentino is past secretary-treasurer of the European Society of Cardiology and current chair of ESC Partnership and Policy Committee. He is ESC chairman of 2019 ESC/EASD Guidelines on diabetes, pre-diabetes and cardiovascular disease and Associate Editor of European Heart Journal.
Professor Giancarlo Agnelli is the Dean of the School of Medicine and Surgery of the University of Perugia, Italy. Prof Giancarlo Agnelli is Professor of Internal Medicine and Director of the Department of Internal Vascular Emergency Medicine and Stroke Unit at the University Hospital in Perugia.
Professor Agnelli is the Editor-in-Chief of the European Journal of Internal Medicine.Professor Agnelli received his medical degree and specialization in Internal Medicine from the University of Perugia.
He was then a research and clinical fellow at the Department of Medicine, McMaster University, Hamilton, Ontario, Canada, and at the Academic Medical Center, University of Amsterdam, The Netherlands.
Professor Agnelli’s research focuses on the clinical trials on the prevention and treatment of cardiovascular disease, including the development of new anticoagulant agents. He is also exploring the relationship between cancer and thrombosis.
Professor Agnelli has authored more than 530 publications (www. pubmed.com). He is also a reviewer for a number of journals including the New England Journal of Medicine, The Lancet, Circulation, Blood, Cardiovascular Research, Journal of Thrombosis and Haemostasis and the Journal of the American College of Cardiology.
Dr. Gemma Vilahur is a Senior Researcher at the Cardiovascular Program ICCC at the Research Institute of the Hospital de la Santa Creu i Sant Pau (Barcelona) where she coordinates the Translational Research Department. Her previous appointments include: Post-doctoral fellowship from the Spanish Ministry of Economy and Competitiveness at the Cardiovascular Biology Research Laboratory, Zena and Michael A. Wiener Cardiovascular Institute at the Mount Sinai School Medicine, New York, USA (2004-2006); Juan de la Cierva Researcher at the Spanish Ministry of Science and Education, (2006-2009); Ramon y Cajal Researcher from the Science and Innovation Ministry of Spain (MICINN; 2010-2015)
She has published 123 articles (Web of Science; 2.962 citations, H index = 31) and include original manuscripts, consensus and position papers, and reviews. In addition, she has contributed to 29 book chapters.She is and has been principal investigator and co-investigator of 40 research projects (National and European projects either funded by public agencies or industry) and has collaborated in two projects of the 7th Framework EU Program. Besides, she has been involved in a CENIT research program (Spanish Ministry of Science and Innovation; 2010-2015).
Dr. Vilahur’s Awards and Honors include: European Society of Cardiology – ESC [Berlin 2002, Vienna 2003, Vienna 2007, Munich 2008 (young investigation award), London 2015]; first Prize National Congress of Cardiology (Madrid 2007; Seville 2012); first and second Prize in the National Congress of Atherosclerosis (Pamplona 2009 and Zaragoza 2013, respectively); Prize from the Northwestern Cardiovascular Young Investigator’s Forum; the Arteriosclerosis, Thrombosis, and Vascular Biology Merit Award of the American Heart Association (AHA; Chicago 2006); and award by L’Oreal-UNESCO foundation – for Women in Science (2012).
Positions of trust: she was elected Nucleus member of the Working Group of Thrombosis of the European Society of Cardiology (2014-2018), further became the treasurer (2016-2018) and she has been recently elected Vice-Chair of this Working Group (2018-2020). She has been elected member of the Council of Basic Cardiovascular Science and member of the ESC Research and Grants Committee (European Society Cardiology; 2018-2020). She is founder of the Scientists of Tomorrow – European Society Cardiology (2013-2016).
As per her contribution in the organization of prestigious scientific courses and meetings: she is member of the organizing committee of the Basic Science Summer Course of the European Society of Cardiology (2017 and 2019); of the Mediterranean League Againts Thromboembolic Disease meeting (Valencia 2014); the Frontiers of Cardiovascular Biology meetings (Barcelona 2014 and Vienna 2018); and she has been the Chair of the ESC-Eurothrombosis meeting last October 2018 (Barcelona).
She has a solid experience in coronary ischemic disease, from atherosclerosis and its cardiovascular risk factors to thrombosis and clinical consequences, as well as in the identification of new targets / therapeutic strategies to prevent and treat ischemic heart disease.
She is the author of four patents (2014, 2016, 2018 and 2019) in the cardiovascular arena and has created two Spin-Offs (2014, 2017).
Have something to say about aspirin?
Please fill in the form below and we will contact you with further information.
Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.
In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.
I received grant support for investigator-initiated research from:
I hold shares in: Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics
I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.
Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.
Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.
AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award
Click here to find the press release.
I received consultant Bayer and Pfizer, Inc.
I received grant support for investigator-initiated research from:
Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
Discipline: Cardiology and Epidemiology
I received consultant and speaker fees Bayer.
I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.
Peter M. Rothwell PhD, MD, FRCP, FMedSci
I received consultant and speakers fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon.
I received grant support for investigator-initiated research from:
Have something to say about aspirin?
We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.